August 16, 2019 – Katie Kosko
August 15, 2019 – Katie Kosko
August 15, 2019 – Jessica Skarzynski
August 15, 2019 – Meeri N. Kim, Ph.D.
August 14, 2019 – Katie Kosko and Brielle Benyon
August 14, 2019 – Kristie L. Kahl
August 14, 2019 – Jessica Skarzynski
August 13, 2019 – Kristie L. Kahl
August 13, 2019 – Meredith Begley and Julie Grisham
FDA Approves Inrebic to Treat Myelofibrosis
The Food and Drug Administration approved Inrebic as the first new treatment in nearly a decade for patients with myelofibrosis.
BY Kristie L. Kahl
PUBLISHED August 16, 2019
The Food and Drug Administration (FDA) approved Inrebic (fedratinib) as the first new treatment in nearly a decade for patients with myelofibrosis, according to Celgene – the agent’s manufacturer.
“Myelofibrosis can cause patients to suffer in many ways, including experiencing debilitating symptoms,” Dr. Ruben Mesa, director of the Mays Cancer Center at UT Health San Antonio Cancer Center MD Anderson, said in a press release. “There has not been a new treatment approved for this disease in nearly a decade. With Inrebic, physicians and patients now have another option available for myelofibrosis.”
Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body’s normal production of blood cells, which can lead to anemia, weakness, fatigue and enlargement of the spleen and liver, among other symptoms.
The agency approved the JAK-2 inhibitor for treatment in patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis based on findings from the JAKARTA trial.
The study demonstrated that patients experienced a 35% or great spleen volume reduction. Serious side effects included cardiac failure (5%) and anemia (2%).
Check back later for more information on what this approval means for patients.
“Myelofibrosis can cause patients to suffer in many ways, including experiencing debilitating symptoms,” Dr. Ruben Mesa, director of the Mays Cancer Center at UT Health San Antonio Cancer Center MD Anderson, said in a press release. “There has not been a new treatment approved for this disease in nearly a decade. With Inrebic, physicians and patients now have another option available for myelofibrosis.”
Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body’s normal production of blood cells, which can lead to anemia, weakness, fatigue and enlargement of the spleen and liver, among other symptoms.
The agency approved the JAK-2 inhibitor for treatment in patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis based on findings from the JAKARTA trial.
The study demonstrated that patients experienced a 35% or great spleen volume reduction. Serious side effects included cardiac failure (5%) and anemia (2%).
Check back later for more information on what this approval means for patients.
Talk about this article with other patients, caregivers, and advocates in the MPN CURE discussion group.